Table 2.
Characteristics of included patients.
| Characteristics | RENAL-AF [19] | AXADIA AFNET 8 [23] | VALKYRIE [22] |
|---|---|---|---|
| Age, (y), (median) | 68 (61-75) | 77 (69-80) | VKA: 80.3 (71.5-84.3) Rivaroxaban: 79.9 (74.4-83.9) Rivaroxaban + Vitamin K2: 79.6 (73.2-83.1) |
| Male sex, No. (%) | 98 (63.6) | 68 (70.1) | 88 (66.7) |
| CHA2DS2-VASc, median (IQR) | 4 (3-5) | 5 (4-6) | 5a |
| HAS-BLED, median (IQR) | NA | 4 (3.5-5) | 5a |
| TTR | 44% | 50.7% | 48% |
| Aspirin, No. (%) | 61 (40.9) | 33 (34.0) | 46 (34.8) |
| Permanent atrial fibrillation, No. (%) | 25 (16.2) | NA | 72 (54.5)= |
| Time on dialysis, median (IQR) | 3.0 (1.5-5.7) y | 962 (363-2147) d | 2.4 ya |
| Black patients, No. (%) | 69 (44.8) | NA | NA |
IQR, interquartile range; NA, not available; No., number; TTR, time in therapeutic range; VKA, vitamin K antagonist.
a
Interquartile range not available for the overall cohort.